Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAX) has earned a consensus rating of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $15.25.

A number of analysts have commented on NVAX shares. B. Riley started coverage on Novavax in a research report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $27.50 price objective on shares of Novavax in a research report on Friday, November 8th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Novavax in a research report on Thursday, October 17th. Citigroup reduced their price objective on Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, September 24th. Finally, Zacks Investment Research downgraded Novavax from a “hold” rating to a “sell” rating in a research report on Friday, January 10th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of Novavax by 10.3% in the 3rd quarter. Rhumbline Advisers now owns 33,428 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 3,118 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Novavax by 473.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 7,166 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 5,917 shares during the last quarter. Creative Planning boosted its position in shares of Novavax by 16.5% in the 3rd quarter. Creative Planning now owns 92,344 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 13,101 shares during the last quarter. State Street Corp boosted its position in shares of Novavax by 3.4% in the 3rd quarter. State Street Corp now owns 424,189 shares of the biopharmaceutical company’s stock worth $2,129,000 after purchasing an additional 14,066 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Novavax in the 2nd quarter worth $435,000. 22.06% of the stock is owned by institutional investors.

Shares of NVAX stock traded up $0.96 during mid-day trading on Wednesday, reaching $5.74. The stock had a trading volume of 9,362,374 shares, compared to its average volume of 2,199,883. The firm’s 50 day simple moving average is $4.26 and its 200 day simple moving average is $4.86. Novavax has a one year low of $3.54 and a one year high of $48.80. The firm has a market cap of $184.37 million, a PE ratio of -0.79 and a beta of 1.93.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.24. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $4.40 million. During the same quarter in the prior year, the business posted ($2.40) EPS. As a group, sell-side analysts expect that Novavax will post -5.7 earnings per share for the current year.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Further Reading: Correction

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.